WuXi AppTec Co., Ltd.
2359.HK
Hong Kong Stock Exchange124.20
HKD
-1.70
- -
WuXi AppTec Co., Ltd.
2359.HK
(Hong Kong Stock Exchange)
Recent
price
124.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- WuXi AppTec Co., Ltd. is a leading global contract research, development, and manufacturing organization (CRDMO) specializing in integrated drug discovery, development, and manufacturing services for pharmaceutical and life sciences companies. Founded in 2000 and headquartered in Shanghai, China, WuXi AppTec offers a comprehensive range of services including small molecule drug discovery and development; active pharmaceutical ingredient (API) and intermediate manufacturing; peptide and oligonucleotide synthesis; biologics development and manufacturing; cell and gene therapy manufacturing (prior to divestment); pharmaceutical and analytical testing; and clinical research services. The company operates globally with significant presence across Asia, Europe, and North America, serving nearly 6,000 partners in more than 30 countries. Recently, WuXi AppTec has focused on expanding its manufacturing capacity and capabilities, especially in small molecule APIs and peptides. In 2024 and 2025, it launched two new peptide manufacturing plants at its Changzhou and Taixing sites in China, boosting solid-phase peptide synthesis reactor volume significantly. The company also enhanced its small molecule API manufacturing volumes, with total reactor volumes expected to exceed 4,000 kiloliters by the end of 2025. WuXi successfully passed FDA inspections at its Changzhou and Taixing API sites with no observations, underscoring its compliance and quality standards. The company launched a new PSD-4 spray dryer at its Taixing API facility in mid-2025 to enhance spray-dried dispersion capabilities. Among strategic changes, WuXi divested its cell and gene therapy manufacturing unit, WuXi Advanced Therapies, selling the US and UK operations to Altaris LLC in early 2025 to sharpen focus on core small molecule and biologics service lines and solidify its "follow-the-customer" and "follow-the-molecule" strategies. In October 2025, WuXi also signed an agreement to sell its China-based clinical research services business to Hillhouse Capital. These moves are part of a broader strategic refinement to accelerate growth in its core contract research, development, and manufacturing segments. WuXi AppTec has also conducted substantial share repurchase programs in 2025 to enhance shareholder value. WuXi AppTec's robust pipeline includes over 3,400 small molecule development projects as of late 2025, with 621 new molecules added in the first three quarters of the year, including commercial projects and late-stage clinical assets. The company supports drug development from early discovery through commercial manufacturing, and between 2024 and mid-2025, it supported the FDA approval of eight small molecule drugs. Financially, WuXi reported strong double-digit revenue growth for the first nine months of 2025, with continuing operations revenue increasing by 22.5% year-over-year to RMB 32.45 billion and a full-year revenue forecast raised to RMB 43.5-44.0 billion, reflecting its market leadership and operational scale. WuXi AppTec remains committed to enabling pharmaceutical innovation globally through its unique CRDMO platform, emphasizing capacity expansion, operational excellence, and strategic portfolio focus to remain a trusted partner across the drug research and manufacturing continuum.